Cough News and Research

RSS

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Merck and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the initiation of a Phase III clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.

21 Apr 2011

Measles alert issued in Tasmania

Tasmanian health authorities have issued an alert over a measles case. They issued a statement revealing that a woman who travelled to Devonport on the Spirit of Tasmania on Monday has been diagnosed with the infectious disease. She was one of four people to contract measles while on board an Air Asia flight from Kuala Lumpur to Melbourne.

17 Apr 2011

Almirall strengthens its respiratory franchise with a new generation of Chronic Obstructive Pulmonary Disease (COPD) treatment

Almirall strengthens its position in the respiratory field with a positive development progress of another New Chemical Entity (NCE). LAS190792 is a new dual long-acting Muscarinic Antagonist β2 Agonist (MABA), which combines two bronchodilator mechanisms in a single molecule for the treatment of COPD.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics, Inc. today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation Annual Meeting in Paris, France.

7 Apr 2011

U.S. Marshals, FDA seize $6 million worth Triad antiseptic products

U.S. Marshals, at the request of the U.S. Food and Drug Administration, today seized more than $6 million in products distributed by Triad Group Inc., at the company's facility in Hartland, Wis.

7 Apr 2011

Novartis' TOBI Podhaler receives Health Canada NOC for Pa treatment in CF patients

Novartis Canada announced today that it has received Health Canada Notice of Compliance for TOBI Podhaler, a fast and convenient inhaled therapy for cystic fibrosis patients aged six and over.

6 Apr 2011

Study finds marked increases in teen use of marijuana and Ecstasy

Following a decade of steady declines, a new national study released today by The Partnership at Drugfree.org and MetLife Foundation indicates that teen drug and alcohol use is headed in the wrong direction, with marked increases in teen use of marijuana and Ecstasy over the past three years.

6 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Geisinger expert offers advice on how to manage child's asthma

Asthma is the leading cause of hospital visits and missed school days in children, according to the National Institute of Health. A chronic condition, pediatric asthma requires continual care to prevent serious, life-threatening asthma attacks.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

ACAAI to launch 15th annual Nationwide Asthma Screening Program

The nation's allergists help adults and children learn if they are at risk for asthma or exercise-induced bronchoconstriction as the American College of Allergy, Asthma and Immunology conducts its 15th annual Nationwide Asthma Screening Program.

31 Mar 2011

Positive results from Vertex VX-770 Phase 3 trial against CF

Vertex Pharmaceuticals Incorporated today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

30 Mar 2011

POET-COPD study looks at controlling 'lung attacks' which can lead to increased ER visits

Chronic Obstructive Pulmonary Disease (COPD) is a major cause for hospital stays and emergency room visits across Canada and researchers say minimizing exacerbations or flare-ups of the disease can go a long way to reducing hospitalizations.

25 Mar 2011

Antibiotic treatment does not benefit patients with discoloured phlegm

Prescribing antibiotics for patients with discoloured phlegm caused by acute cough has little or no effect on alleviating symptoms and recovery, a Cardiff University study has found.

25 Mar 2011

Study demonstrates superiority of Spiriva over salmeterol in reducing risk of exacerbations in COPD

Results of the one-year Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD®) study, published today by the New England Journal of Medicine (NEJM), demonstrate that Spiriva® (tiotropium), is superior to salmeterol, in reducing the risk of exacerbations in Chronic Obstructive Pulmonary Disease (COPD).

24 Mar 2011

Department of Health acting Secretary stresses need to raise TB awareness

Department of Health acting Secretary Dr. Eli Avila today stressed the need to raise public awareness of tuberculosis, or TB, and the importance of efforts to control—and eventually eliminate—the infectious airborne disease.

24 Mar 2011

USP teams up with FDA, CHPA to update quality standards for common medications

As part of its ongoing mission to protect public health, the U.S. Pharmacopeial Convention is working with the Food and Drug Administration and the Consumer Healthcare Products Association to update quality standards for widely used medicines and ingredients.

22 Mar 2011

TB risk in infants exposed to infected health worker

Around 200 families have been exposed and probably infected with infectious Tuberculosis (TB) after a hospital health worker was diagnosed with the disease. At present the health care worker is off work and is receiving treatment. The hospital said there was no continuing risk to patients and staff.

16 Mar 2011